Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new advanced automation capabilities on its EPIQ CVx and EPIQ CVxi cardiac ultrasound systems. With Release 5.0, both the EPIQ CVx and EPIQ CVxi now include automated applications for 2D assessment of the heart, as well as robust 3D right ventricle volume and ejection fraction measurements, making accurate exams faster and easier to conduct [1]. Together, the new applications provide clinicians with the means to confidently evaluate the heart’s function, increasing diagnostic confidence for patients with pulmonary hypertension, congenital heart disease, coronary disease and heart failure.
“The complexity of cardiac exams can be a barrier to accessing high quality care. Philips is addressing this by leveraging Artificial Intelligence to make echo exams easier, faster and more reproducible,” said David Handler, General Manager of Cardiac Ultrasound at Philips. “By incorporating advanced automation, there is less variability between scans, leading to accurate treatment decisions which benefits patients. The new release of EPIQ CVx is a major step forward, reducing the number of touches of the system by 21% in each exam, which is equivalent to more than 400 exams each year [2].”